International Journal of Diabetes Mellitus
Volume 1, Issue 1 , Pages 16-21 , April 2009

Identification of loci conferring risk for premature CAD and heterozygous familial hyperlipidemia in the LDLR, APOB and PCSK9 genes

  • Paul Muiya

      Affiliations

    • MBC-03-05, Genetics Department, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia
    • ,
  • Salma Wakil

      Affiliations

    • MBC-03-05, Genetics Department, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia
    • ,
  • Mohamed Al-Najai

      Affiliations

    • MBC-03-05, Genetics Department, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia
    • ,
  • Brian F. Meyer

      Affiliations

    • MBC-03-05, Genetics Department, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia
    • ,
  • Futwan Al-Mohanna

      Affiliations

    • Biological and Medical Research, King Faisal Specialist Hospital and Research Centre (MBC-03), P.O. Box 3354, Riyadh 11211, Saudi Arabia
    • ,
  • Maie Alshahid

      Affiliations

    • King Faisal Heart Institute, King Faisal Specialist Hospital and Research Centre (MBC-03), P.O. Box 3354, Riyadh 11211, Saudi Arabia
    • ,
  • Nduna Dzimiri

      Affiliations

    • MBC-03-05, Genetics Department, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia
    • Corresponding Author InformationCorresponding author. Tel.: +966 1 442 7870; fax: +966 1 4424585.

Received 13 March 2009 ,Accepted 30 March 2009.

References 

  1. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4(4):214–225
  2. Soutar AK, Naoumova RP. Autosomal recessive hypercholesterolemia. Semin Vasc Med. 2004;4(3):241–248
  3. Yang KC, Su YN, Shew JY, Yang KY, Tseng WK, Wu CC, et al. LDLR and ApoB are major genetic causes of autosomal dominant hypercholesterolemia in a Taiwanese population. J Formos Med Assoc. 2007;106(10):799–807
  4. Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet. 2006;78(3):410–422
  5. Chen SN, Ballantyne CM, Gotto AM, Tan Y, Willerson JT, Marian AJ. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005;45(10):1611–1619
  6. Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem. 2004;279(48):50630–50638
  7. Maxwell KN, Breslow JL. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. Curr Opin Lipidol. 2005;16(2):167–172
  8. Scartezini M, Hubbart C, Whittall RA, Cooper JA, Neil AH, Humphries SE. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy UK men. Clin Sci (Lond). 2007;113(11):435–441
  9. Berge KE, Ose L, Leren TP. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol. 2006;26(5):1094–1100
  10. Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet. 2004;65(5):419–422
  11. Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, et al. PCSK9-dependent LDL receptor regulation: effects of pH and LDL. J Biol Chem. 2007;
  12. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161–165
  13. Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet. 2006;43(12):943–949
  14. Zhu H, Tucker HM, Grear KE, Simpson JF, Manning AK, Cupples LA, et al. A common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterol. Hum Mol Genet. 2007;16(14):1765–1772
  15. Knoblauch H, Bauerfeind A, Toliat MR, Becker C, Luganskaja T, Gunther UP, et al. Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Hum Mol Genet. 2004;13(10):993–1004
  16. Bourbon M, Sun XM, Soutar AK. A rare polymorphism in the low density lipoprotein (LDL) gene that affects mRNA splicing. Atherosclerosis. 2007;195(1):e17–20
  17. Linsel-Nitschke P, Gotz A, Erdmann J, Braenne I, Braund P, Hengstenberg C, et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease – a Mendelian Randomisation study. PLoS ONE. 2008;3(8):e2986
  18. Benn M, Stene MC, Nordestgaard BG, Jensen GB, Steffensen R, Tybjaerg-Hansen A. Common and rare alleles in apolipoprotein B contribute to plasma levels of low-density lipoprotein cholesterol in the general population. J Clin Endocrinol Metab. 2008;93(3):1038–1045
  19. Liao YC, Lin HF, Rundek T, Cheng R, Hsi E, Sacco RL, et al. Multiple genetic determinants of plasma lipid levels in Caribbean Hispanics. Clin Biochem. 2008;41(4-5):306–312
  20. Tosi I, Toledo-Leiva P, Neuwirth C, Naoumova RP, Soutar AK. Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic. Atherosclerosis. 2007;194(1):102–111
  21. Humphries SE, Cranston T, Allen M, Middleton-Price H, Fernandez MC, Senior V, et al. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J Mol Med. 2006;84(3):203–214
  22. Cheng X, Ding J, Zheng F, Zhou X, Xiong C. Two mutations in LDLR gene were found in two Chinese families with familial hypercholesterolemia. Mol Biol Rep. 2008;
  23. Mozas P, Castillo S, Tejedor D, Reyes G, Alonso R, Franco M, et al. Molecular characterization of familial hypercholesterolemia in Spain: identification of 39 novel and 77 recurrent mutations in LDLR. Hum Mutat. 2004;24(2):187
  24. Chater R, Ait Chihab K, Rabes JP, Varret M, Chabraoui L, El Jahiri Y, et al. Mutational heterogeneity in low-density lipoprotein receptor gene related to familial hypercholesterolemia in Morocco. Clin Chim Acta. 2006;373(1-2):62–69
  25. Tybjaerg-Hansen A, Jensen HK, Benn M, Steffensen R, Jensen G, Nordestgaard BG. Phenotype of heterozygotes for low-density lipoprotein receptor mutations identified in different background populations. Arterioscler Thromb Vasc Biol. 2005;25(1):211–215
  26. Horvath A, Savov A, Kirov S, Karshelova E, Paskaleva I, Goudev A, et al. High frequency of the ApoB-100 R3500Q mutation in Bulgarian hypercholesterolaemic subjects. J Med Genet. 2001;38(8):536–540
  27. Horvath A, Ganev V. The mutation APOB-100 R3500Q in Eastern Europe. Atherosclerosis. 2001;156(1):241–242
  28. Ding K, Kullo IJ. Molecular population genetics of PCSK9: a signature of recent positive selection. Pharmacogenet Genomics. 2008;18(3):169–179
  29. Ceska R. Familial apolipoprotein B-100 defect, a newly discovered lipid metabolism disorder. Cas Lek Cesk. 1994;133(22):686–689
  30. Gasparovic J, Basistova Z, Fabryova L, Wsolova L, Vohnout B, Raslova K. Familial defective apolipoprotein B-100 in Slovakia: are differences in prevalence of familial defective apolipoprotein B-100 explained by ethnicity?. Atherosclerosis. 2007;194(2):e95–107
  31. Taylor A, Tabrah S, Wang D, Sozen M, Duxbury N, Whittall R, et al. Multiplex ARMS analysis to detect 13 common mutations in familial hypercholesterolaemia. Clin Genet. 2007;71(6):561–568
  32. Dedoussis GV. Apolipoprotein polymorphisms and familial hypercholesterolemia. Pharmacogenomics. 2007;8(9):1179–1189
  33. Real JT, Chaves FJ, Ejarque I, Garcia-Garcia AB, Valldecabres C, Ascaso JF, et al. Influence of LDL receptor gene mutations and the R3500Q mutation of the apoB gene on lipoprotein phenotype of familial hypercholesterolemic patients from a South European population. Eur J Hum Genet. 2003;11(12):959–965
  34. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA. 2005;102(15):5374–5379
  35. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006;116(11):2995–3005
  36. Pisciotta L, Priore Oliva C, Cefalu AB, Noto D, Bellocchio A, Fresa R, et al. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis. 2006;186(2):433–440
  37. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40(2):161–169
  38. Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol. 2007;18(3):304–309
  39. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514–523
  40. Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008;48(2):646–654
  41. Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, Poupon V, et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic. 2007;8(6):718–732
  42. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem. 2004;279(47):48865–48875
  43. Sun XM, Eden ER, Tosi I, Neuwirth CK, Wile D, Naoumova RP, et al. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet. 2005;14(9):1161–1169
  44. Miyake Y, Kimura R, Kokubo Y, Okayama A, Tomoike H, Yamamura T, et al. Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis. 2007;
  45. Lambert M, Assouline L, Feoli-Fonseca JC, Brun N, Delvin EE, Levy E. Determinants of lipid level variability in French–Canadian children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2001;21(6):979–984
  46. Xie L, Gong QH, Xie ZG, Liang ZM, Hu ZM, Xia K, et al. Two novel mutations of the LDL receptor gene associated with familial hypercholesterolemia in a Chinese family. Chin Med J (Engl). 2007;120(19):1694–1699
  47. Jensen HK. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark. Dan Med Bull. 2002;49(4):318–345
  48. Assouline L, Levy E, Feoli-Fonseca JC, Godbout C, Lambert M. Familial hypercholesterolemia: molecular, biochemical, and clinical characterization of a French–Canadian pediatric population. Pediatrics. 1995;96(2 Pt 1):239–246
  49. Civeira F, Ros E, Jarauta E, Plana N, Zambon D, Puzo J, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol. 2008;102(9):1187–11931193–1181
  50. Ejarque I, Real JT, Martinez-Hervas S, Chaves FJ, Blesa S, Garcia-Garcia AB, et al. Evaluation of clinical diagnosis criteria of familial ligand defective apoB 100 and lipoprotein phenotype comparison between LDL receptor gene mutations affecting ligand-binding domain and the R3500Q mutation of the apoB gene in patients from a South European population. Trans Res. 2008;151(3):162–167
  51. Scartezini M, Hubbart C, Whittall RA, Cooper JA, Neil AH, Humphries SE. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in UK healthy men. Clin Sci (Lond). 2007;
  52. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007;32(2):71–77

PII: S1877-5934(09)00017-4

doi: 10.1016/j.ijdm.2009.05.003

International Journal of Diabetes Mellitus
Volume 1, Issue 1 , Pages 16-21 , April 2009

Article Tools